RxDoctor Payments Data

Clara Choo, MD

Ophthalmology · Bloomington, MNNPI 1760746028

Payments from drug & device makers

$447in general payments, 2019–2025

Across 11 payments — averaging $40.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$117
  • Ocular Therapeutix, Inc.$101
  • AbbVie$67
  • Carl Zeiss Meditec, Inc.$65
  • Oyster Point Pharma, Inc.$40
  • Alcon$20
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$40791%
  • Education$409%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$447 in reported general payments places this provider in the 55th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$276,382
Medicare patients
420
Services billed
2,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate258$115,463
LumiganBimatoprost51$30,635
RestasisCyclosporine25$26,899
Latanoprost1,034$17,916
Prednisolone Acetate504$15,609
Travoprost58$15,419
RocklatanNetarsudil Mesylat/Latanoprost29$13,669
Alphagan PBrimonidine Tartrate37$11,963
MoxifloxacinMoxifloxacin Hcl517$10,917
Dorzolamide-TimololDorzolamide/Timolol/Pf59$10,387
Brimonidine Tartrate299$9,883
Ketorolac Tromethamine566$9,465
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat492$9,465
CombiganBrimonidine Tartrate/Timolol28$8,085
Fluorometholone110$7,265

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$67$77,582141 claims
AlconSimbrinza$20$4,17122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Bloomington

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →